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UCLA School of Medicine, Los Angeles, California 90024-1769; and II Department of Neurology and Neuroscience, Cornell 
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Abstract. Neurons and endocrine cells have two types 
of secretory vesicle that undergo regulated exocytosis. 
Large dense core vesicles (LDCVs) store neural pep- 
tides whereas mall clear synaptic vesicles tore clas- 
sical neurotransmitters such as acetylcholine, "r-amino- 
butyric acid (GABA), glycine, and glutamate. 
However, monoamines differ from other classical 
transmitters and have been reported to appear in both 
LDCVs and smaller vesicles. To localize the trans- 
porter that packages monoamines into secretory vesi- 
cles, we have raised antibodies to a COOH-terminal 
sequence from the vesicular amine transporter x- 
pressed in the adrenal gland (VMAT1). Like synaptic 
vesicle proteins, the transporter occurs in endosomes 
of transfected CHO cells, accounting for the observed 
vesicular transport activity. In rat pheochromocytoma 
PC12 cells, the transporter occurs principally in 
LDCVs by both immunofluorescence anddensity gra- 
dient centrifugation. Synaptic-like microvesicles in
PC12 cells contain relatively little VMAT1. The results 
appear to account for the storage of monoamines by 
LDCVs in the adrenal medulla nd indicate that 
VMAT1 provides a novel membrane protein marker 
unique to LDCVs. 
N 
EUROTRANSMITTERS are stored in secretory vesicles 
that undergo regulated exocytosis. Peptide transmit- 
ters enter the secretory compartment by co-trans- 
lational translocation ofa precursor protein into the lumen 
of the endoplasmic reticulum and subsequently undergo pro- 
cessing and packaging into mature vesicles (de Camilli and 
Jahn, 1990; Trimble et al., 1991; Kelly, 1991). In contrast, 
the synthesis of classical transmitters such as acetylcholine, 
3'-aminobutyric a id (GABA),t glycine, glutamate, and the 
biogenic amines occurs in the cytoplasm. These transmitters 
also appear in the cytoplasm after emoval from the synapse 
by specific plasma membrane r uptake systems (Amara and 
Kuhar, 1993). Thus, classical transmitters equire specific 
transport from the cytoplasm for packaging into secretory 
vesicles. In addition, the storage of neural peptides and clas- 
sical transmitters occurs in distinct vesicle populations. 
Address all correspondence to R. H. Edwards, Department of Neurology, 
UCLA School of Medicine, 710 Westv, x~xl Blvd., Los Angeles, CA 90024- 
1769. Ph.: (310) 206-7672. Fax: (310) 206-2502. 
1. Abbreviations used in this paper: CGAT, chromaflin granule amine trans- 
porter; DBH, doparnine #-hydroxylase; DFP, diisopropylfluorophosphate; 
GABA, 3,-aminobutyric a id; HBS, Hepes-buffered saline; KLH, keyhole 
limpet hemocyanin; LDCV, large dense core vesicles; MBS, m-maleimido- 
benzoyl N-hydroxysuccinimide; MPP +, N-methyl-4-phenylpyridinium; 
mppres, Mpp + resistant; NGS, normal goat serum; PAM, peptidylglycine 
c~-amidating monooxygenase; VMAT1, vesicular amine transporter. 
Neural cells store peptide transmitters in large dense core 
vesicles (LDCVs), the functional equivalent of the secretory 
granules in which endocrine cells store peptide hormones 
(Kelly, 1991; Trimble et al., 1991). These granules range in 
size from 40 to over 100 nm and have a characteristic dense 
core in electron micrographs, presumably due to their pro- 
tein content. LDCVs also have a relatively diffuse distribu- 
tion in the cytoplasm. They appear in nerve terminals but not 
at the same high density as classical synaptic vesicles; they 
also occur in the cell body and dendrites. In contrast, neu- 
rons store classical transmitters uch as acetylcholine, 
GABA, glycine, and glutamate in small clear synaptic vesi- 
cles of 40-50 nm (Sudhof and Jahn, 1991; Edwards, 1992). 
Typical synaptic vesicles cluster in large numbers at the 
nerve terminal, in close proximity to the presynaptic mem- 
brane. In addition to these differences instructure and local- 
ization, large dense core vesicles and synaptic vesicles also 
differ in function. Exocytosis from LDCVs occurs with a 
longer latency after stimulation than exocytosis from synap- 
tic vesicles (de Camilli and Jahn, 1990). The observed 
differences inrate of release presumably account for the rela- 
tively prolonged action of peptides as neural modulators and 
the more rapid action of classical neurotransmitters in direct 
signaling. In addition, high frequency stimulation favors re- 
lease from LDCVs relative to synaptic vesicles (Andersson 
et al., 1982). Differential sensitivity to u-latrotoxin (Mat- 
teoli et al., 1988), and intracellular calcium (Rane et al., 
© The Rockefeller University Press, 0021-9525/94/12/1419/15 $2.00 
The Journal of Cell Biology, Volume 127, Number 5, December 1994 1419-1433 1419 
1987; Martin and Magistretti, 1989) further indicates that 
exocytosis from the two types of vesicle involves distinct 
mechanisms. Thus, the storage of peptide and classical 
transmitters in different vesicular compartments has clear 
implications for the regulation of their release and for their 
role in synaptic transmission. Since the packaging of classi- 
cal transmitters into vesicles requires transport from the 
cytoplasm, the selective packaging of specific transmitters 
into different types of vesicles depends on the expression of 
specific transport activities by these different vesicles. 
Previous tudies have identified at least four distinct vesic- 
ular transport activities: one for the biogenic amines, a sec- 
ond for acetylcholine, another for GABA and glycine and a 
fourth for glutamate (Sudhof and Jahn, 1991; Edwards, 
1992). The availability of bovine adrenal chromaffin gran- 
ules and their robust ransport activity have made the vesicu- 
lar transport of monoamines a prototype for vesicular neu- 
rotransmitter transport. Studies using this preparation have 
shown that vesicular amine transport depends on a pH 
gradient generated by the vesicular H+-ATPase (Kanner 
and Schuldiner, 1987; Johnson, 1988). The transporter x- 
changes two lumenal protons for a cytoplasmic amine. Re- 
cent studies have shown that the vesicular transporters for 
other classical transmitters depend on different aspects of the 
same H+-electrochemical gradient (Anderson et al., 1982; 
Maycox et al., 1988; Hell et al., 1990). However, classical 
transmitters donot all appear to be stored in the same vesicu- 
lar compartment. Typical small synaptic vesicles express 
specific transport activities for acetylcholine, GABA, gly- 
cine, and glutamate, consistent with storage in this compart- 
ment (Burger et al., 1989). On the other hand, cells in the 
adrenal medulla store monoamines with neural peptides in 
large dense core chromaffin granules (Johnson, 1988). In the 
central nervous ystem, neurons tore monoamines in small 
vesicles that may contain a dense core depending on the 
method of fixation (Smith, 1972; Thureson-Klein, 1983). 
Thus, the storage of monoamines appears to differ from that 
of other classical transmitters and presumably reflects the 
differential sorting of vesicular transport proteins. 
Using selection in the neurotoxin N-methyl-4-phenylpyri- 
dinium (MPP÷), we have recently cloned a eDNA encoding 
the chromaffin granule amine transporter (CGAT) or vesicu- 
lar amine transporter (VMAT1) (Liu et al., 1992b; Erickson 
et al., 1992). The transporter protects against this toxin by 
sequestering it in intracellular vesicles, away from its pri- 
mary site of action in mitochondria (Liu et al., 1992a). The 
sequence predicts aprotein with twelve transmembrane do-
mains and weak homology to several bacterial antibiotic re- 
sistance transporters (Liu et al., 1992b). We have now used 
the amino acid sequence deduced from this eDNA to design 
a synthetic peptide, produce polyclonal antisera to the trans- 
porter and determine its intracellular location. The results 
indicate xpression of the transporter in endocytic vesicles 
of CHO fibroblasts and preferential expression i LDCVs of 
neuro-endocrine PC12 cells. 
Material and Methods 
Cell Culture 
CHO cells were maintained in Ham's F-12 medium with 5% FCS and rat 
pheochromocytoma PC12 cells in modified DME with 10% horse serum 
and 5% FCS. All cultures were kept at 37°C in 5% CO2 and all media con- 
tained penicillin and streptomycin. 
CHO cells were co-transfected as previously described (Liu et al., 
1992a) with 10 #g of the VMATI eDNA in the plasmid expression vector 
CDM8 and 1 ttg of the selectable marker Rous sarcoma virus-neomycin 
(RSV-neo) per 10 cm plate. After initial selection in 400 #g/ml G418 for 
2 wk, the cells were selected again in 1 mM MPP + for at least 3 wk. 
MPP+-resistant (mpp res) cells were maintained in the absence of the toxin 
for at least 1 wk before study. 
To label the dense core granules with [3H]norepinephrine, PCI2 cells 
were incubated in standard medium containing 5 #Ci [3H]noradrenaline 
(Amersham Corp., Arlington Heights, IL)/25 ml for at least 6 h before cell 
fractionation. 
Peptide Synthesis and Antibody Production 
The peptide CGENSDDPSSGE was synthesized manually and coupled to 
keyhole limpet hemocyanin (KLH) through the NH2-terminal cysteine 
using m-maleimidobenzoyl N-hydroxysuccinimide ester (MBS). For the 
primary inoculation, 150 #g of the conjugated peptide was emulsified in 
complete Freund's adjuvant and injected intradermally into adult female 
rabbits (Harlow and Lane, 1988). Antibody production was boosted 4 wk 
later by the subcutaneous injection of 100/~g conjugated peptide mulsified 
in incomplete Freund's adjuvant. After 12 d, the animals were bled through 
an ear vein. The antibody titer following the first boost was then measured 
using the unconjugated peptide in a solid-phase ELISA (Harlow and Lane, 
1988). Animals making anti-peptide antibodies were then boosted further 
with 100 p,g of conjugated peptide at 4-wk intervals, with serum collected 
2 wk after each boost. The anti-peptide antibodies were purified on a pep- 
tide affinity column of epoxy-activated Sepharose 6B (Pharmacia Fine 
Chemicals, Piscataway, NJ). For adsorption, the antibody was diluted 1:100 
in 500 #10.1% Tween-20/PBS, 0.5 mg peptide added, the mixture incubated 
overnight at 4°C, and then diluted further in the same solution for immuno- 
staining. 
Immunostaining 
For immunocytocherrtistry, cells cultured overnight in a 24-well plate were 
fixed in 4% paraformaldehyde/0.1 M PBS, pH 7.2, permeabilized in 0.2% 
Triton X-100/PBS for 15 rain and blocked with 5% nonfat dry milk in PBS 
for 30 rain at room temperature. The cells were then incubated for 60 rain 
with the primary antibody diluted 1:1,000-1:5,000 in 1% nonfat dry 
milk/PBS and washed three times in PBS, each for 5 rain. Incubation in a 
secondary biotinylated anti-rabbit antibody (Vector Labs, Burlingame, CA) 
was also carried out for 30 rain, followed by three 5-rain washes in PBS. 
The complexes were visualized using avidin-biotin conjugated to alkaline 
phosphatase (Vector Labs). 
For immunocytochemistry of the adrenal gland, adult, male Sprague- 
Dawley rats were anesthetized with sodium pentobarbital (50 mg/kg i.p.) 
and perfused through the ascending aorta with 4% paraformaldehyde/0.1 M 
sodium phosphate, pH 7.2. The adrenal gland was then dissected, postfixed 
again in the same solution for an additional hour at room temperature, in- 
cubated in 30% sucrose at 4°C overnight, frozen, sectioned at 10 #m, and 
the tissue collected on gelatin-coated slides for immunocytochemistry as 
described above. 
For immunofluorescence, both CHO and PCI2 cells were grown on glass 
coverslips to 60-80% confluence and processed as described (Schweitzer 
and Paddock, 1990). PC12 cells were treated with 10 ng/ml NGF in 
medium containing serum for four days before staining. The cells were then 
fixed as described above, permeabilized in 0.1% Triton X-100/Hepes- 
buffered saline (HBS), and then incubated with anti-peptide antibody 
diluted 1:1,000 in 1% normal goat serum (NGS)/HBS. After washing in 
HBS, the cells were incubated at room temperature with goat anti-rabbit 
antibody conjugated to fluorescein diluted 1:100 in 1% NGS/HBS, washed 
again, and visualized with epifluorescence. Double staining with WGA con- 
jugated to Texas red and monoclonal antibodies to tubulin, secretogranin 
I, and synaptophysin was carried out simultaneously. The mouse antibodies 
were visualized by incubation with a biotinylated sheep anti-mouse anti- 
body followed by streptavidin-Texas red (Amersham Corp.). 
To identify transferrin receptors, the CHO cells were pre-incubated in 
serum-free medium at 37°C for 60 min to remove ndogenous transferrin, 
incubated with 20 #g/ml human transferrin conjugated toTexas red (Molec- 
ular Probes, Eugene, OR) for an additional 30 min, rinsed quickly in cold 
medium without ransferrin, and then fixed and the cells examined under 
epifluorescence. 
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Membrane Preparation and Cell Fractionation 
Cell membranes were prepared as described previously (Liu et al., 1992b). 
Briefly, cells rinsed twice in cold FIBS containing 5 mM MgEGTA were 
detached from the substrate by scraping in FIBS with EGTA supplemented 
by 1 t~g/ml leupeptin and 0.2 mM diisopropylfluoro-phosphate (DFP). The 
cells were then homogenized byrepeated passage through aball-beating de- 
vice (European Molecular Biology Labs, Heidelberg, Germany) at a clear- 
ante of 10/~m. The nuclei and other cell debris were pelleted by centrifuga- 
tion at 750 g for 5 min. To prepare membranes, the supernatant was 
centrifuged again at 35,000 rpm in a Beckman SW50.1 for 45 rain at 4"C 
and the pellet resuspended in either FIBS or electrophoresis ample buffer 
(67.5 mM Tris, pH 6.8, 3% SDS, 10% glycerol, 5% 2-mereaptoethanol). 
For cell fractionation by equilibrium sedimentation, the postnuclear su- 
pernatant was layered onto a linear 0.6-1.6 M sucrose gradient in 10 mM 
Hepes for sedimentation at 30,000 rpm for 6 h in an SW41 rotor (Beckman 
Instruments, Palo Alto, CA) at 4°C. Fractions were collected from the bot- 
tom of the tube and stored at -70"C. The protein content was monitored 
using the Bradford assay (Bio-Rad Laboratories, Richmond, CA) and the 
radioactivity of fractions from ceils pre-loaded with [3H]norepinephrine 
measured in Eeolume (ICN Biomedicals, Irvine, CA) using a Beckman 
3800 scintillation counter. 
For velocity sedimentation through glycerol, the post-nuclear superna- 
tant was centrifuged ina SW50.1 (Beckman Instruments) at48,000 rpm for 
1 h at 4"C through 5-25 % glycerol in FIBS containing 1mM EGTA (Clift- 
O'Grady et al., 1990) and the fractions processed as described above. FOr 
metrizamide gradients, the postnuclear supernatant from ceils disrupted in 
0.32 M sucrose/4 mM Hepes, pH 7.4/0.5 mM EDTA (SH buffer) was cen- 
trifuged for 2.25 h at 55,000 rpm in a 70.1 Ti rotor (Beckman Instruments) 
through 10-23 % metrizamide over a cushion of 35 % metrizamide, with the 
10 and 23% stock solutions of metrizamide prepared by dilution of 35% 
metrizamide with SH buffer (Green et al., 1994), and the fractions pro- 
cessed in the same way as the other gradients. 
Gel Electrophoresis and Western Blot Analysis 
Postnuclear supernatants and aliquots from fractions of the sucrose gradient 
were diluted in 2 x sample buffer and separated by electrophoresis through 
10% SDS-polyacrylamide containing 6 M urea. The resulting els were 
transferred tonitrocellulose (BA-S NC; Schleicher & Schuell) using a semi- 
dry electrotransfer apparatus (E&K Scientific Products Inc., Saratoga, CA). 
Aliquots from the metrizamide and glycerol gradients were immobilized on 
nitrocellulose dot blots. The filters were then blocked in 0.1% Tween- 
20/PBS (TBS) containing 5% nonfat dry milk, incubated in primary anti- 
body for 60 min in TBS with 1% nonfat dry milk, washed three times in 
TBS and then incubated with secondary antibody conjugated toperoxidase. 
The immune complexes were visualized by chemiluminescence (Amersham 
Corp.) and quantitated by densitometry. 
Metabolic Labeling and Immunoprecipitation 
CHO and PCI2 cells at moderately high density were metabolically labeled 
with [3SS]cysteine and methionine (Translabel; ICN Biomedicals) at 0.25 
mCi/ml in cysteine- and methionine-free m dium supplemented by 1% dia- 
lyze, d FCS. When indicated, tunicamycin was added at 20 ng/ml to inhibit 
N-linked glycosylation. After labeling for 6 to 12 h, the cells were rinsed 
with PBS, detached from the substrate by scraping in 1% sodium deoxycho- 
late, 1% Triton X-100, 0.2% SDS, 150 mM NaCI, 50 mM Tris, pH 7.4 
(RIPA buffer) containing 20 p.g/ml PMSE and the nuclear debris removed 
by centrifugation. 
For immunoprecipitation, theresuspended ceils were diluted to a final 
volume of 1 ml RIPA and incubated overnight at 4°C with afffinity-purified 
anti-peptide antibody at a dilution of 1:1,000. The antigen-antibody com- 
plexes were precipitated by incubation for 4 h at 4°C with 200 #1 10% 
prewashed protein A sepharose (Sigma Chemical Co., St. Louis, MO) and 
the precipitates washed three times in RIPA (Edwards et al., 1988). The 
beads were then resuspended in 50 #12 x sample buffer and 25 t~l separated 
by electrophoresis through 10% SDS-polyacrylarnide containing 6 M urea. 
After electrophoresis at 10-25 mA, the gels were fixed in 10% acetic 
acid/50% methanol for 20 min, impregnated with 1 M sodium salicylate 
for 20 rain, dried, and exposed to film at -70°C with an enhancing screen. 
N-Glycanase Digestion 
For N-glycanase digestion, the immunoprecipitate obtained as described 
above from PC12 cells metabolically abeled with [3SS]cysteine and methi- 
onine was resuspended in 0.5% SDS/50 mM fl-mercaptoethanol/50 mM
NaPO4, pH 8. 20 t~g protein was then digested with 0.3 U of N-glycanase 
(G-enzyme Corp., Boston, MA) in the presence or absence of 1.2% NP-40 
at 37°C overnight, he reaction stopped by dilution in sample buffer, and 
the products analyzed by electropboresis through polyacrylamide contain- 
ing SDS. 
Immunoisolation 
Fixed S. aureus cells were pre-coated with: (a) rabbit VMATI anti-peptide 
antibody; and (b) rabbit anti-goat antisera s control by incubation with 
gentle rotation in 150 mM NaCI, 10 mM Hepes, pH 7.4, 1 mM EGTA, 
1 mM MgCl2, 1% BSA (buffer A) for 2 h at 4°C. The cells were then 
washed three times in buffer A and incubated with postnuclear supernatants 
containing ",,30,000 dpm from PCI2 cells pre-labeled with [3H]norepi- 
nephrine as described above. For immunoisolation with the SV2 antibody, 
Staphylococcus aureus cells were pre-coated first with a rabbit anti-mouse 
antibody; then with (c) mouse SV2 monoclonal ntibody; and (d) normal 
mouse serum as control. After incubation of the cell extracts with the pre- 
coated beads for 2 h at 40C, the mixtures were precipitated bycentrifugation 
at 1,000 g and the radioactivity inthe supernatant determined by liquid scin- 
tillation counting. Subtraction of the radioactivity in the supernatant from 
the total radioactivity yielded the radioactivity in the immunoprecipitated 
vesicles. 
Immunoelectron Microscopy 
Methods for tissue preparation and immunolabeling were based on those 
described by Leranth and Pickel (1989). Adult male Sprague-Dawley rats 
(250-350 g) were anesthetized as described above with sodium pentobarbi- 
tal and perfused with 40 ml heparinized saline (l,000 U/ml beparin in 0.15 
M NaCl) followed by 50 ml 3.75 % acrolein and then by 200 ml 2 % parafor- 
maldehyde/0.1 M sodium phosphate, pH 7.4. The adrenal glands were re- 
moved, postfixed in 3.75% acrolein for 30 min and sections cut on a vibra- 
tome at 40 #m. The sections were then incubated for 30 min in 1% sodium 
borohydride/0.1 M sodium phosphate, pH 7.4 to remove reactive aldehydes 
and rinsed repeatedly in0.1 M sodium phosphate, pH 7.4. The sections were 
cryo-protected for 15 min in 25% sucrose/3.5% glycerol/0.05 M sodium 
phosphate, pH 7.4 and rapidly freeze-thawed in chlorodifluoromethane fol- 
lowed by liquid nitrogen. 
Sections were incubated in anti-VMAT1 antibody diluted !:12,000 in 
0.1% BSA/0.15 M NaCI/25 mM Tris, pH 7.6, and the bound antibodies 
identified with an avidin-biotin complex (Hsu et al., 1981). Briefly, the sec- 
tions were incubated first for 30 min in a 1:50 dilution of biotinylated goat 
anti-rabbit IgG in 0.1% BSA and then for 30 rain in a l:100 dilution of the 
peroxidase-avidin-biotin complex. The tissue was then incubated for 6 min 
in Tris-buffered saline containing diaminobenzidine and hydrogen peroxide 
to visualize the bound peroxidase. 
Sections were fixed in 2% osmium tetroxide for 60 min and fiat embed- 
ded in Epon 812 between two pieces of Aclar plastic. Ultrathin sections 
were collected from the outer surface of the plastic-embedded tissue using 
an RMC ultramicrotome, counterstained with lead citrate, and examined 
using a Phillips 201 electron microscope. 
Results 
Production and Characterization f VMAT1 Antibody 
Although the sequence of VMAT1 indicates an extremely hy- 
drophobic protein with 12 predicted transmembrane do- 
mains and few antigenic regions, we synthesized a 16-amino 
acid peptide from the relatively hydrophilic COOH terminus 
and added a cysteine to the NH2 terminus of the sequence 
for coupling through MBS to the carrier KLH. After immu- 
nization, rabbit sera were screened for the presence of anti- 
bodies using a peptide ELISA. Animals producing anti- 
bodies to the peptide were boosted again and their sera tested 
further by immunostaining MPP + resistant CHO cells trans- 
fected with the VMAT1 eDNA (Liu et al., 1992b). 
The antisera from one rabbit recognized the VMAT1 pro- 
tein in transfected but not wild-type CHO cells (Fig. 1). The 
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Figure 1. Immunostaining with an anti-peptide antibody shows a particulate cytoplasmic pattern of VMAT1 expression in transfected CHO 
fibroblasts. CHO cells transfected with the VMAT1 cDNA and selected in MPP+ (a and b) and untransfected wild-type CHO cells (c 
and d) were immunostained with an anti-peptide antibody to VMAT1 at a dilution of 1:2,000 and visualized by phase contrast (a and c) 
and epi-fluorescence (b and d). The transfected cells show a particulate pattern of cy oplasmic fluorescence very similar to that seen previ- 
ously for pre-loaded dopamine (Liu et al., 1992a), whereas wild-type cells show no immunoreactivity. Comparison of the phase contrast 
and fluorescence micrographs shows that the foc lconcentration f fluorescence observed in transfected cells is outside of but adjacent 
to the nuclei. Bar, 10 #m. 
perinuclear and scattered particulate cytoplasmic staining 
strongly resembled the distribution of intracellular dopa- 
mine observed after loading these same MPP+-resistant 
cells with exogenous dopamine (Liu et al., 1992a). To char- 
acterize the antibody further, we tested its ability to detect 
VMAT1 by Western blotting (Fig. 2). Wild-type CHO cells 
expressed no immunoreactive protein whereas transfected 
MPP+-resistant cells expressed large amounts of an ,055- 
kD protein and smaller but still substantial mounts of an 
,095-kD protein. Rat pheochromocytoma PC12 cells, from 
which the VMAT1 cDNA originally derived, expressed 
small amounts of the 55-kD protein, and variable amounts 
of a higher molecular weight form of ,0120 kD. In both cell 
types the size differed from previous work indicating apro- 
tein of ,075 kD in bovine chromaffin granules (Stern-Bach 
et al., 1990; Vincent and Near, 1991; Isambert et al., 1992) 
but the species origin of the cDNA from rat and the use of 
urea in the gel system may alter the electrophoretic mobility 
of this extremely hydrophobic protein. In addition, previous 
studies have concentrated on one f the two transport iso- 
forms separated by isoelectric focusing (Stern-Bach et 
al., 1990). The differences in amount of VMATI expressed 
by the different cells are consistent with variations in the 
amount of VMAT1 mRNA previously observed in CHO 
transfectants and PC12 cells (Liu et al., 1992b). In addition, 
adsorption of the antibody with the peptide liminated these 
immunoreactive species on Western blots (data not shown). 
Although the antisera had a titer of 1:1,000-1:2,000 and pro- 
duced relatively low background staining in transfected 
cells, the antibody was further purified on a peptide affinity 
column (Pharmacia Biotech Inc.) and used at a dilution of 
1:10,000-1:20,000. 
To characterize the ability of the anti-peptide antibody to 
recognize VMAT1 in vivo, we have also used the antiserum 
to immunostain sections of the rat adrenal gland. Fig. 3 a 
shows strong staining of chromaffin cells in the adrenal 
medulla nd no staining of cortical cells. As expected for a 
vesicle protein, the medullary cell immunoreactivity was 
principally cytoplasmic and did not include the nucleus. Ad- 
sorption with the peptide eliminated hemedullary staining 
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Figure 2. The anti-peptide anti- 
body recognizes VMAT1 by West- 
ern blot analysis. 25/zg of protein 
from a membrane preparation of 
wild-type CHO cells, CHO cells 
stably transfected with VMAT1 
and selected in MPP + (MP/~'), 
and wild-type PC12 cells were 
separated by electrophoresis 
through 10% polyacrylamide-SDS 
containing 6 M urea, blotted to 
nitrocellulose, stained with the 
anti-peptide VMAT1 antibody at a 
dilution of 1:2,000, and the reac- 
tion visualized by chemi-lumi- 
nescence (Amersham Corp.). 
Transfected CHO cells contain ex- 
tremely large amounts of an ap- 
proximately 55-kD protein (ar- 
row) as well as higher molecular 
weight forms whereas wild-type 
CHO cells contain no immunore- 
active material. PC12 cells contain 
smaller amounts of the ~55-kD 
protein (arrow) as well as higher 
molecular weight forms that vary 
in intensity. 
(Fig. 3 b). The origin of the cortical staining remains unclear 
and was occasionally but not always reduced by peptide ad- 
sorption as well. 
Localization of VMAT1 to Endocytic Vesicles 
in Transfected ClIO Cells 
The transfection ofcDNAs for synaptic vesicle proteins into 
nonneural cells has led to their localization at a number of 
characteristic intracellular sites. Heterologous expression of 
synaptophysin in CHO fibroblasts results in protein localiz- 
ing to vesicles that concentrate at the microtubule organizing 
center; this staining co-localizes with the transferrin recep- 
tor that marks a population of recycling microvesicles (John- 
ston et al., 1989; Cameron et al., 1991). In contrast, the 
vesicle protein synaptotagmin appears at the plasma mem- 
brane when expressed in CHO cells (Feany et al., 1993). 
The demonstration f vesicular amine transport activity in 
membranes prepared from transfected CHO cells (Liu et al., 
1992b) suggested that the transporter localizes to intracellu- 
lar vesicles containing a vacuolar H+-ATPase and so resem- 
bles the targeting of synaptophysin rather than synap- 
totagmin. 
In MPP+-resistant CHO cells, the particulate pattern of 
glyoxylic acid-induced fluorescence after loading with exog- 
enous dopamine suggests he presence of VMATI in intracel- 
lular vesicles (Liu et al., 1992a). Immunostaining with the 
antibody to VMAT1 supported this impression (Fig. 4). 
Double-staining with an antibody to tubulin further indi- 
cated that the peri-nuclear site of protein accumulation coin- 
cides with the microtubule organizing center (Fig. 4, b and 
c) and double staining with WGA demonstrated substantial 
steady-state expression i the vicinity of the Golgi complex 
(Fig. 4, e and f ) .  To determine whether the amine trans- 
porter specifically localizes to a population of recycling vesi- 
cles, we incubated the living cells with human transferrin 
conjugated toTexas red for 30 min and then stained the c lls 
for the transporter. Colocalization of the tagged human trans- 
ferrin with the immunoreactive transport ro ein strongly 
supported the presence of the transporter in a population of 
recycling vesicles (Fig. 5). Sucrose density gradients also 
demonstrated the coincidence of vesicles containing the 
transferrin receptor with those containing the amine trans- 
porter (data not shown). Thus, the heterologous expression 
of VMAT1 in CHO cells results in targeting of the trans- 
porter in a manner similar to that of other neuronal vesicle 
proteins uch as synaptophysin a d SV2 (Johnston et al., 
1989; Cameron et al., 1991) and differs from the localization 
previously reported for synaptotagmin (Feany et al., 1993). 
The results further indicate that the vesicular amine trans- 
porter contains by itself the signals for sorting to the endo- 
cytic pathway and does not rely on association with another 
synaptic vesicle protein. Sorting to a population of acidic 
vesicles thus allows functional expression of the transporter 
in a nonneural cell line. 
Localization of VMATI in PC12 Cells to Large Dense 
Core Vesicles 
To determine the intracellular localization of VMAT1 in 
neuro-endocrine cells that store monoamines, we have exam- 
ined the distribution of the endogenous protein expressed by 
PC12 cells. As noted above, the anti-VMAT1 antibody recog- 
nizes the vesicular amine transporter expressed by these 
cells. Further, these typically round cells can be treated with 
NGF to induce the formation of neural processes and so 
facilitate intracellular localization. Immunostaining with the 
antibody to VMAT1 shows predominant expression of the 
antigen in the ends of processes (Fig. 6), with relatively little 
staining in the cell bodies. To determine the relationship of 
this immunoreactivity o dense core granules, we have 
stained the same cells with an antibody to secretogranin I, 
a soluble protein of LDCVs, and found the same pattern of 
distribution in the tips of processes. Thus, VMAT1 co- 
localizes with secretogranin I. Since previous tudies have 
demonstrated the differential distribution of LDCVs and 
SLMVs in NGF-treated PC12 cells (Schweitzer and Pad- 
dock, 1990), we performed similar double-staining with an- 
tibodies to VMAT1 and the synaptic vesicle protein synap- 
tophysin, which appears at much higher levels in SLMVs 
than in dense core granules (Navone t al., 1986). In contrast 
to secretogranin, immunostaining of NGF-treated PC12 
cells with the antibody to synaptophysin showed expression 
predominantly in cell bodies and to a lesser extent at the ends 
of processes. Staining of the same cells with the anti-VMAT1 
antibody indicated a distinct pattern of distribution, with 
most expression i the processes. Thus, the morphologic ex- 
amination of PC12 cells by light microscopy indicates ex- 
pression of VMAT1 in dense core granules and suggests its 
relative xclusion from SLMVs. 
To characterize further the subcellular distribution of 
VMATI in PC12 cells, we have also fractionated the cells by 
equilibrium sedimentation through sucrose density gradients 
(Schweitzer and Kelley, 1985). The dense core granule frac- 
tion was identified by pre-loading the c lls with [3H]norepi- 
nephrine (Fig. 7 A). An immunoblot f the fractions tained 
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Figure 3. Adrenal medullary 
cells express VMAT1. Sec- 
tions from the rat adrenal 
gland were stained with the 
anti-peptide antibody to 
VMAT1 (a) and with the same 
antibody after adsorption with 
the peptide used to generate it 
(b). All cells in the adrenal 
medulla (arrows) but none in 
the cortex react with the anti- 
body. Adsorption with the 
peptide eliminates the medul- 
lary immunoreactivity en- 
tirely and reduces the punc- 
tate staining observed to 
varying degrees in the cortex. 
Bar, 150 #m. 
with an antibody to secretogranin II indicated that this pro- 
tein resides as expected in the heavier, dense core granules 
also pre-labeled with [3H]norepinephrine (Fig. 7 B). In 
contrast, an antibody to synaptophysin labeled 'predomi- 
nantly a lighter fraction of vesicles distinct from the peak of 
soluble protein, with variable but substantially ower levels 
of expression in the dense core granule fraction. The 
anti-peptide antibody to VMATI detected the 55-kD form 
of the protein in the peak of LDCVs centered at fraction 6. 
No immunoreactive protein of this size appeared in the 
lighter fractions. However, the immunoreactive material 
migrating at ,,o120 kD appeared in both heavy and light 
membrane fractions. To determine whether this material is 
VMAT1 or unrelated background, we immunostalned an- 
other Western blot containing fractions from the gradient 
with a preparation of antibody that had been adsorbed with 
the peptide used to generate it. Pre-adsorption with the pep- 
tide abolished the staining of both the 55- and ,,ol20-kD 
bands, indicating that both of these species contain VMATI. 
Thus, the endogenous vesicular amine transporter expressed 
by PC12 cells occurs in two forms, a low molecular weight 
form that appears to reside exclusively in LDCVs and a 
higher molecular weight form that predominates in dense 
fractions but also occurs in lighter membranes, possibly 
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Figure 4. VMAT1 immunofluorescence in transfected CHO fibroblasts co-localizes with the microtubule-organizing center and the Golgi 
complex. Stable CHO transformants expressing VMATI were viewed by phase contrast (a and d) and immunostained.with the polyclonal 
rabbit VMAT1 antibody (b and e),a mouse monoclonal antibody to tubulin (c) and WGA conjugated to Texas red (f). For double staining 
of the two sets ofcells (a-c and d-f), the VMAT1 rabbit antibody was visualized with a secondary antibody conjugated to fluorescein 
and the mouse anti-tubulin antibody with a secondary antibody conjugated to Texas red. Thestrong punctate peri-nuclear VMAT1 im- 
munoreactivity (arrows, b) co-localizes with the microtubule organizing center (arrows, c). Additional peri-nuclear VMAT1 staining (ar- 
rows, e) co-localizes with wheat germ agglutinin (arrows, f). Bar, 10 #m. 
SLMVs or plasma membrane vesicles. The higher molecular 
weight form usually but not always (Fig. 2) predominates in 
PC12 cells, independent of the method of analysis (by West- 
ern blot of cell homogenates or immunoprecipitation f 
metabolically abeled cell extracts). However, the high mo- 
lecular weight form does not simply occur as soluble protein 
since it had a higher density distinct from the peak of soluble 
protein that appeared at the top of the gradient. 
Large membrane proteins, particularly those with multi- 
ple predicted transmembrane domains, have a tendency to 
aggregate, possibly accounting for the higher molecular 
weight form of VMAT1 observed in PC12 cells. However, 
preparation ofthe extracts from transfected CHO cells under 
the identical conditions did not yield the same species, sug- 
gesting that a modification specific to PC12 cells is responsi- 
ble for this form. To characterize this modification further, 
we metabolically abeled both CHO and PC12 cells, immu- 
noprecipitated VMAT1 from the postnuclear supernatant 
and treated the precipitates with N-glycanase to remove 
N-linked carbohydrate. As expected from the immunoblots, 
wild-type CHO cells expressed no detectable VMAT1 (Fig. 
8) whereas the MPP+-resistant CHO transformants ex- 
pressed proteins of ,055 and ,095 kD. Treatment with 
N-glycanase reduced both of these to a species migrating at 
,040 kD. The immunoprecipitate from PC12 cells also con- 
tained small amounts of a protein of ,055 kD in addition to 
larger amounts of the ,0120-kD protein seen on immuno- 
blots. Interestingly, treatment of this immunoprecipitate 
with N-glycanase r sulted in increased amounts ofa ,050-kD 
protein. This indicated that the high molecular weight form 
of VMAT1 expressed in PC12 cells does not represent ag- 
gregates but rather extensive N-linked carbohydrate modi- 
fication. Pulse-chase studies confirm a precursor-product 
relationship between the two forms (Liu, Y., and R. H. Ed- 
wards, manuscript in preparation). The failure to reduce the 
proteins in PC12 cells to the size obtained after digestion of 
the proteins expressed in CHO cells further suggests either 
incomplete digestion or a second modification ot removed 
by N-glycanase. The treatment of PC12 cells with tunicamy- 
cin also showed reduction of the principal species to only 
,,050 kD (data not shown), suggesting that a second modi- 
fication is responsible. We have identified asimilar high mo- 
lecular weight form of the transporter in Western blots of 
protein extracted from the rat adrenal gland (data not 
shown), indicating that this modification is not unique to 
PC12 cells and occurs in vivo as well. 
Both Endosomes and Synaptic-like Microvesicles 
Contain Small Amounts of VMAT1 
Quantitation of immunoblots by densitometry shows that 
65% VMAT1 occurs in LDCVs and 19% in lighter fractions. 
This preferential localization t  LDCVs differs from that of 
other membrane proteins that occur in both compartments. 
In contrast to VMAT1, 42 % SV2 immunoreactive protein re- 
sides in LDCVs and 49% in lighter fractions (data not 
shown). To localize the VMAT1 immunoreactivity that ap- 
pears in lower density fractions on the sucrose gradient, we
have used additional density gradients. Light vesicle frac- 
tions from the sucrose gradient may contain endosomes, 
SLMVs or both. To determine whether VMAT1 occurs on 
endosomes as well as LDCVs, we have used sedimentation 
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Figure 5. VMAT1 immunofluorescence co-localizes with a popula- 
tion of recycling endocytic vesicles. Stable CHO transformants ex- 
pressing VMAT1 were pre-incubated with human transferrin con- 
jugated to Texas red for 30 min and immunostained for VMAT1. 
Visualization of VMAT1 immunoreactivity with a secondary anti- 
body conjugated o fluorescein (a) shows a virtually identical pat- 
tern of labeling to the transferrin receptor (b) as a marker ofrecy- 
cling endocytic vesicles. Bar, 10 ttm. 
through metrizamide. Fig. 9 shows that on this gradient 
LDCVs containing secretogranin II sedimented more rapidly 
than endosomal membranes containing the transferrin recep- 
tor and SLMVs expressing synaptophysin. VMATI appeared 
at both sites in the gradient, reflecting localization to the 
more rapidly sedimenting LDCVs and by a lighter vesicle 
fraction, either SLMVs or endosomes. Lighter membranes 
contain virtually no secretogranin II, presumably because 
the soluble contents of LDCVs are secreted rather than 
recycled. 
To separate ndosomes from SLMVs, we used velocity 
sedimentation through glycerol (Fig. 10). Using this gra- 
dient, transferrin receptor, secretogranin and pre-loaded 
[3H]norepinephrine localized to the bottom of the gradient 
whereas apeak of synaptophysin was present in the middle. 
Thus, SLMVs do not sediment as rapidly as endosomes 
and LDCVs in this gradient. A fraction of VMAT1 co- 
sedimented with synaptophysin, indicating localization on 
SLMVs. The analysis of VMAT1 localization in CHO cells 
and the study of other vesicle proteins would predict sig- 
nificant argeting of VMAT1 to endosomes; these gradients 
are consistent with such a localization although they do not 
explicitly prove it. 
Nonspecific monoamine uptake or uptake by a transport 
protein distinct from VMAT1 may mediate storage in vesi- 
cles that do not express VMAT1. To examine this possibility, 
we have used the antibody to VMAT1 to isolate vesicles from 
PC12 cells pre-incubated with [3H]norepinephrine. If vesi- 
cles that do not contain VMAT1 store monoamines, we 
would only be able to immunoisolate a fraction of the total 
stored radioactivity using this antibody. As a positive con- 
trol, we used the vesicle membrane protein SV2 which oc- 
curs on both LDCVs and SLMVs (Schweitzer and Kelly, 
1985). The monoclonal ntibody to SV2 immunoisolates all 
of the radiolabeled transmitter inthe preloaded vesicles (Fig. 
11). The VMAT1 antibody also precipitated essentially all 
the [3H]norepinephrine contained in vesicles, excluding up- 
take into a distinct compartment. 
lmmunoelectron Microscopic Localization of VMATI 
in ChromaJfin Granules 
To determine the subcellular distribution of VMAT1 in vivo, 
we have used immunoelectron microscopy. Fig. 12 shows 
labeling of the rat adrenal medulla with the antibody to 
VMAT1 visualized with peroxidase. The antibody-labeled 
chromaffin granules but not the nucleus, early Golgi com- 
plex or mitochondria. At higher esolution (Fig. 13), the an- 
tibody also labeled the ndoplasmic reticulum and trans- 
Golgi network. Thus, immunoreactivity forVMAT1 occurs 
at several sites in the secretory pathway but most promi- 
nently in the chromaffin granules, supporting the results in 
PC12 cells. Sympathetic nerve fibers entering the adrenal 
medulla contain occasional LDCVs and abundant small clear 
vesicles that do not react with the antibody (Fig. 13 b). In 
contrast to the sympathetic innervation of other peripheral 
tissues, sympathetic nnervation of the adrenal gland in- 
volves direct projection of the preganglionic neuron to the 
target without an intervening post-ganglionic neuron. Since 
pre-ganglionic neurons use acetylcholine as their neuro- 
transmitter rather than monoamines, ympathetic nerve ter- 
minals within the adrenal gland would not be expected to ex- 
press a vesicular amine transporter. In addition, we have 
found that post-ganglionic sympathetic neurons express 
VMAT2 rather than VMAT1 (D. Peter, C. Sternini, N. 
Brecha, and R. H. Edwards, preliminary observations). 
Discussion 
Using an antibody raised against he COOH terminus of the 
vesicular amine transporter xpressed in the adrenal gland, 
we have localized the protein in transfected CHO fibroblasts 
to a population of recycling endocytic vesicles. By im- 
munofluorescence, the transporter co-localizes with recy- 
cling transferrin receptors. In addition, peri-nuclear staining 
co-localizes with markers for the microtubule organizing 
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Figure 6. Endogenous VMAT1 immunofluorescence in PC12 cells co-localizes with LDCVs rather than SLMVs. PC12 cells were treated 
with NGF (10 ng/ml) for 4 d before staining. Three sets of cells (a-c, d-f and g-i) were viewed by phase contrast (a,d, and g), stained 
with the rabbit VMATI antibody (b and e) and the same antibody after ads rption with the peptide used to generate it (h) and the reactions 
visualized with a secondary antibody conjugated to fluor scein. The same cells were double-stained with a mouse monoclonal antibody 
to secretogranin I (c and i) and synaptophysin (f). VMAT1 appears predominantly at the tips of neuritic processes rather than the cell 
body and control serum shows no immunoreactivity (h). Further, VMAT1 co-localizes with secretogranin I (c), a markerfor LDCVs. In 
contrast, VMAT1 staining appears distinct from synaptophysin (f), a marker for SLMVs. Bar, 10 #m. 
center and the Golgi complex. The results account for the de- 
tection of vesicular amine transport activity in membranes 
prepared from the stable VMAT1 transformants even though 
these cells lack a known secretory compartment for regu- 
lated release such as synaptic vesicles or LDCVs. Transport 
activity depends on a H÷-electrochemical gradient across 
the vesicle membrane and several of the compartments in 
which the transporter apparently occurs such as the endo- 
somes and Golgi complex contain a vacuolar H÷-ATPase 
that can generate such a gradient (Rudnick, 1986; Forgac, 
1989). 
The sorting of VMATI in CHO cells Strongly resembles 
that of other synaptic vesicle proteins such as synaptophysin 
when they are expressed in fibroblasts (Johnston et al., 1989; 
Cameron et al., 1991). These observations indicate that the 
vesicular amine transporter contains its own signals for en- 
docytosis. Recycling of the transporter f om the cell surface 
after exocytotic fusion therefore does not require association 
with other synaptic vesicle proteins. Indeed, the expression 
of other synaptic vesicle proteins in CHO fibroblasts appears 
to result in distinct patterns of localization. In contrast o 
synaptophysin, synaptotagmin targets to the plasma mem- 
brane and SV2 targets to a population of vesicles that ex- 
cludes the transferrin and low density lipoprotein receptors 
as markers of the recycling endosomal pathway (Feany et al., 
1993). Interestingly, the vesicular amine transporter resem- 
bles synaptophysin more than these two other synaptic vesi- 
cle proteins in terms of targeting in CHO cells even though 
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Figure 7. Distribution ofVMAT1 by equilibrium sucrose density gradient fractionation f PC12 cells. PC12 cells were pre-loaded overnight 
with [3H]norepinephrine a d a postnuclear supernatant loaded onto a 0.6-1.6 M continuous sucrose gradient, with fractions collected 
from the bottom. (A) Distribution of total protein on the gradient shows two peaks, one centered at fraction 6 and the other at fraction 
18. Radioactivity also accumulates in a peak centered at fraction 6 that presumably contains LDCVs. (B) Western blot analysis of the same 
fractions shown in A for VMAT1, secretogranin II, and synaptophysin, as described in Fig. 2. VMAT1 localizes with secretogranin to 
LDCVs whereas synaptophysin occurs predominantly in lighter membranes (but not soluble proteins as shown in A). VMAT1 occurs in 
two forms, the ~55-kD form also seen in CHO cells and a higher molecular weight form not seen in CHO cells. The high molecular 
weight form predominates in the heavier membrane fractions and is the only form seen in lighter fractions. 
Figure 8. VMAT1 contains variable but substantial mounts of 
N-linked glycosylation. Wild type and transfected (MPP ~s) CHO 
cells and PC12 cells were metabolically labeled with [35S]cysteine 
and methionine overnight and the postnuclear supernatants immu- 
noprecipitated with the VMAT1 antibody. The immunoprecipitates 
were then digested without and with N-glycanase and separated by 
electrophoresis as de cribed inFig. 2. Wild-type CHO cells contain 
no immunoprecipitated protein whereas stable VMAT1 transfor- 
mants contain the '~55- and ~100-kD proteins een on Western 
blots. Treatment with N-glycanase reduces the majority of these 
species to *40 kD. The unusually high mobility of this protein both 
before and particularly after N-glycanase digestion presumably 
reflects the anomalous electrophoretic behavior of an extremely hy- 
drophobic protein rather than degradation. In PC12 cells, the high 
molecular weight form predominates over a faint but detectable 
band at '~55 kD and is reduced to ~50 kD by N-glycanase 
(arrows). 
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Figure 9. VMAT1 occurs predominantly onfractions correspond- 
ing to LDCVs. A post-nuclear supernatant of PC12 cells prela- 
beled with [3H]norepinephrine was fractionated by sedimentation 
through metrizamide and the fractions collected from the bottom. 
The upper panel shows the percentage of metrizamide in each frac- 
tion and the middle panel the total protein and ra ioactivity in each 
fraction. The lower panel shows the densitometric quantitations of 
VMAT1, secretogranin II (Sgll), transferrin receptor (TfR), and 
synaptophysin (P38) immunoreactivity from dot blots stained with 
the appropriate antibodies. The immunoreactivity for each of the 
fractions tained with one antibody was added and the percentage 
of the total in each fraction is shown. Secretogranin II and [3H]- 
norepinephrine label a broad peak of LDCVs centered at fraction 
7. VMAT1 labels this same broad peak but also occurs in lighter 
membrane fractions containing the transferrin receptor and synap- 
tophysin as markers for endosomes and SLMVs respectively. 
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Figure 10. VMAT1 occurs on SLMVs by glycerol velocity gradient 
fractionation. PC12 cells were pre-labeled with [3H]norepineph- 
rine, a postnuclear supernatant sedimented through glycerol and 
the fractions collected from the bottom. The top panel shows the 
percentage of glycerol in each fraction. The middle panel shows to- 
tal protein and radioactivity while the bottom panel indicates per- 
centage of total immunoreactivity for each of the antibodies de- 
scribed in Fig. 9. VMAT1 roughly co-localizes with synaptophysin 
(P38) in lighter membrane fractions, indicating expression in 
SLMVs. VMAT1 also occurs in heavier membrane fractions that 
contain LDCVs as indicated by the [3H]norepinephrine a d se- 
cretogranin II. 
sorting of the transporter and synaptophysin differ strongly 
in neuro-endocrine PC12 cells. 
In PC12 cells, previous work using the measurement of 
transport activity has suggested localization of the vesicular 
amine transporter in LDCVs (Bauerfeind et al., 1993). We 
have now used an antibody to identify preferential local- 
ization of the transport protein in LDCVs both by immu- 
nofluorescence analysis of doubly stained cells and by cell 
fractionation using a variety of gradients. Immunoelectron 
microscopy of adrenal medullary cells also shows staining of 
chromaffin granules but the paucity of SLMVs in these cells 
makes it difficult o exclude apresence in that compartment 
as well. In addition, PC12 ceils may contain more LDCVs 
than SLMVs but the substantial expression of other synaptic 
vesicle membrane proteins uch as SV2 and synaptotagmin 
in both compartments (Buckley et al., 1985; Walch-Soli- 
mena et al., 1993) or such as synaptophysin predominantly 
in SLMVs (Navone t al., 1986) makes the preferential local- 
ization of the amine transporter in LDCVs unique. The bio- 
genesis of LDCVs and synaptic vesicles differ in several im- 
portant respects. LDCVs in neurons and secretory granules 
in endocrine cells originate from the trans-Golgi network 
(Burgess and Kelly, 1987; Trimble et al., 1991). Selected 
proteins such as neural peptides ort into this regulated 
secretory pathway through poorly characterized mecha- 
nisms. After fusion with the plasma membrane, components 
of the dense core granule membrane may recycle to the Golgi 
Figure 11. Immuno-isolation f pre-loaded [3H]norepinephrine 
with the antibody to VMAT1. PCI2 cells were pre-labeled with 
[3H]norepinephrine a d a post-nuclear supernatant incubated with 
S. aureus cells pre-coated with the antibody o VMAT1 and a 
monoclonal antibody to the vesicle proteoglycan SV2 (stippled 
bars). Both the VMAT1 and SV2 antibodies isolate all the [3H]- 
norepinephrine pre-loaded into vesicles as measured by sedi- 
menting all the cellular membranes at high speed (total). Staphylo- 
coccus cells pre-coated with control rabbit serum in the case of 
VMAT1 and control mouse serum in the case of SV2 (open bars) 
precipitated substantially less of the pre-loaded [3H]norepi- 
nephrine. 
complex for refilling and re-release. In contrast, synaptic 
vesicles from neurons or SLMVs from endocrine cells ap- 
pear to originate from early endosomes (Kelly, 1991). The 
synaptic vesicle protein synaptophysin occurs at only very 
low levels in dense core granules (Navone t al., 1986), sug- 
gesting that synaptic vesicles do not derive from recycled 
granule membrane components (Cutler and Cramer, 1990). 
Rather, synaptophysin travels directly to the plasma mem- 
brane in the constitutive secretory pathway and synaptic 
vesicles appear to bud off early endosomes (Clifi-O'Grady 
et al., 1990; Regnier-Vigouroux et al., 1991). Thus, LDCVs 
derive from the regulated secretory pathway and SLMVs 
from the constitutive secretory pathway. The mechanism for 
sorting of proteins into these two pathways remains unclear. 
However, membrane proteins uch as synaptophysin serve to 
distinguish SLMVs from LDCVs and may enable dissection 
of the relevant sorting signals. On the other hand, LDCVs 
contain soluble proteins and membrane-associated proteins 
absent from the constitutive pathway and synaptic vesicles. 
These proteins may sort into the regulated pathway through 
aggregation but a clear sorting signal has not been identified 
(Burgess and Kelly, 1987). However, VMAT1 now provides 
a clear membrane protein uniquely associated with LDCVs 
and not SLMVs. 
In addition to neural peptides, several membrane proteins 
localize preferentially toLDCVs rather than to synaptic vesi- 
cles or SLMVs. These proteins include cytochrome b561 
that mediates the reduction of intravesicular scorbate, the 
processing enzyme peptidylglycine c~-amidating monoox- 
ygenase (PAM), and dopamine/3-hydroxylase (DBH). DBH 
does not contain a membrane-spanning domain but associ- 
ates with the lumenal face of the vesicle membrane, xclud- 
ing the possibility ofsorting signals on the cytoplasmic sur- 
face of the vesicle. PAM occurs in two forms, one soluble 
and the other attached to the vesicle membrane at the 
COOH-terminus (Milgram et al., 1993, 1994). The two 
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Figure 12. VMAT1 localizes to chromaftin cells exposed to the reagents for immunolabeling. Electron micrographs of chromaflin cells 
in the adrenal medulla (a) immunolabeled for VMAT1 and (b) not exposed to the immunoreagents. The most prominent immunolabel- 
ing in a occurs in chromaffin granules (curved arrows). Immunoreaction product is notably absent from the chromatfin cell nucleus (N) 
and from axon terminals (t) of adjacent neurons. In b, the pattern of immunolabeling seen in a is absent from tissue not exposed to the 
reagents. (L, lysosome; m, mitochondria. Bar, 2 #m. 
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Figure 13. VMAT1 immunoreactivity localizes to chromafiin granules and not he synaptic vesicles of adjacent neuronal processes. (a) 
Electron micrograph showing immunoperoxidase reaction product for VMAT1 in most chromaflin granules (curved arrows). Less conspicu- 
ous labeling for VMAT1 occurs in smaller vesicles in the trans-Golgi network (/arge arrows) and in both endoplasmic reticulum and free 
polyribosomes ( mall arrows). In contrast, immunoreaction product for VMAT1 cannot be detected in mitochondria (m) or early Golgi 
apparatus (G). (b) Higher magnification electron micrograph of the boxed region in Fig. 12 a. Intense labeling for VMAT1 occurs in a 
large population of chromaffin granules (curved arrows), but cannot be detected in either the small clear vesicles (scv) or the dense core 
vesicles (dcv) of adjacent axon terminals. (N, nucleus of chromaftin cell; open arrow, outer membrane of chromaffin cell. Bar, 0.5 t~m. 
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forms differ in their trafficking through the cell but both sort 
to LDCVs, indicating the importance of interactions within 
the interior of the vesicle for targeting to this pathway. It also 
remains unclear whether PAM occurs in synaptic vesicles. 
Cytochrome b561 has six predicted transmembrane domains 
(Perin et al., 1988; Kent and Fleming, 1990) and thus differs 
from DBH and PAM in its membrane topology. Although the 
cytochrome appears in both LDCVs and synaptic vesicles 
(Walch-Solimena et al., 1993), it is predominantly localized 
to the SLMV peak, suggesting that the vesicular amine trans- 
porter may be a more specific integral membrane protein for 
the regulated secretory pathway. 
The transporter may resemble soluble proteins that are 
specific for LDCVs and sort into the pathway through lu- 
menal domains. Recent evidence suggests that interactions of 
this type may confer sorting to the apical pathway in pola- 
rized epithelial cells (Fiedler et al., 1994). The identification 
of extensive N-linked glycosylation on the transporter ex- 
pressed in PC12 cells but not fibroblasts further raises the 
possibility of interaction with lectins that may play a role in 
polarized targeting. However, sorting may also occur by in- 
teraction of the transmembrane and cytoplasmic domains 
with specific proteins of a protein sorting machinery. 
Velocity gradient centrifugation through glycerol indicates 
that a relatively small proportion of the total vesicular amine 
transporter occurs in SLMVs. The small amounts of protein 
may account for the failure to observe vesicular amine trans- 
port activity in SLMVs prepared on sucrose density gra- 
dients, particularly when adjacent fractions containing en- 
dosomes express ubstantial transport activity (Bauerfeind et 
al., 1993). The transporter could appear in SLMVs by two 
distinct mechanisms. First, incomplete sorting to the regu- 
lated pathway could result in some of the transport protein 
reaching the cell surface through the constitutive pathway. 
Second, the transporter could arrive at the plasma mem- 
brane following the fusion of LDCVs. In both cases, the 
transporter may sort into SLMVs after endocytosis. Al- 
though the amine transporter in SLMVs represents a small 
fraction of the total transporter in PC12 cells, neurons in the 
central nervous system appear to store monoamines in small 
synaptic vesicles (Smith, 1972; Thureson-Klein, 1983). The 
identification of small amounts of the adrenal transporter in 
PC12 SLMVs raises the possibility that central neurons use 
a similar pathway to sort the transporter into synaptic vesi- 
cles. Neurons may simply increase the efficiency of sorting 
to this pathway. Alternatively, the vesicular amine trans- 
porter expressed in the brain may contain signals different 
from the adrenal transporter that increase the efficiency of 
this sorting. 
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